Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities

The Rapha Capital Mission is to use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities.

Rapha Capital Management is focused on identifying and growing revolutionary ideas in medicine, healthcare and technology before others can see their value.

Rapha Capital Management, LLC, founded in mid-2018, has grown to include 13 managed entities, Rapha Capital Investment I – XIII.

Poseida Therapeutics Logo

Poseida Therapeutics, Inc.

NexImmune Icon

NexImmune, Inc.

Rapha Capital Latest News


December 7, 2022 in 3DBio Therapeutics, Inc., Portfolio, Rapha Capital Management

Popular Science Magazine Names 3D Bio Therapeutics “Best of What’s New – 2022” Grand Award Winner in Health for AuriNovo™

– 3D Bio is the first company implanting 3D-bioprinted living tissues in patients – – Rapha Capital Management, LLC has…
Read More
August 22, 2022 in IMAGIN Medical, Portfolio, Rapha Capital Management

Imagin Medical Announces Acquisition of the enCAGE Coil™ Precision Ablation System for Prostate Cancer and a New $7.25M Convertible Note to Finance Its Development

Rapha Capital BioVentures Fund I, LP (Rapha Capital), and Bigger Capital lead the financing. VANCOUVER, BC, and BOSTON, MA, August…
Read More
July 25, 2022 in K2 Biolabs, Ponce Therapeutics, Portfolio, Rapha Capital Management

Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma’s Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies in Anti-Aging and Other Products Initially for Skin

Ponce Therapeutic’s (“Ponce”) lead product, ReBeaut™, is a microneedle patch containing nanoparticles carrying its proprietary ApoptiCIDe™ cell elimination gene therapy technology targeting…
Read More